BTAI BioXcel Therapeutics | $1.93
-2.0% | 3/19/2025 | Initiated by | Rodman & Renshaw | Analyst Elemer Piros | Buy | $65.00 | High | View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/19/2025 |
TELO Telomir Pharmaceuticals | $1.18
-7.1% | 2/21/2025 | Initiated by | Rodman & Renshaw | - | Buy | $15.00 | High | View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/21/2025 |
PYPD PolyPid | $3.49
-1.1% | 1/28/2025 | Initiated by | Rodman & Renshaw | - | Buy | $13.00 | High | View details for Rodman & Renshaw rating of PolyPid (NASDAQ:PYPD) on 1/28/2025 |
INMB INmune Bio | $2.36
+12.9% | 1/28/2025 | Initiated by | Rodman & Renshaw | - | Buy | $23.00 | Medium | View details for Rodman & Renshaw rating of INmune Bio (NASDAQ:INMB) on 1/28/2025 |
CRDL Cardiol Therapeutics | $1.39
+5.3% | 1/28/2025 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Medium | View details for Rodman & Renshaw rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025 |
ATRA Atara Biotherapeutics | $8.25
+5.8% | 12/20/2024 | Initiated by | Rodman & Renshaw | - | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024 |
HURA TuHURA Biosciences | $2.61
+5.7% | 12/19/2024 | Initiated by | Rodman & Renshaw | - | Buy | $11.00 | N/A | View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024 |
FBLG FibroBiologics | $0.61
+1.6% | 12/12/2024 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of FibroBiologics (NASDAQ:FBLG) on 12/12/2024 |
RMTI Rockwell Medical | $0.82
-1.5% | 11/14/2024 | Initiated by | Rodman & Renshaw | - | Buy | $5.00 | N/A | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024 |
OMER Omeros | $3.09
+4.0% | 11/14/2024 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 11/14/2024 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
EPRX Eupraxia Pharmaceuticals | $5.47
-6.3% | 11/14/2024 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024 |
ACHV Achieve Life Sciences | $2.26
+1.8% | 11/14/2024 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024 |
BCAX Bicara Therapeutics | $9.20
-2.7% | 11/5/2024 | Initiated by | Rodman & Renshaw | - | Buy | $48.00 | Low | View details for Rodman & Renshaw rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024 |
QNCX Quince Therapeutics | $1.60
+5.3% | 10/29/2024 | Initiated by | Rodman & Renshaw | - | Buy | $11.00 | Medium | View details for Rodman & Renshaw rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024 |
ANRO Alto Neuroscience | $2.33
+5.0% | 10/23/2024 | Downgraded by | Rodman & Renshaw | - | Buy -> Neutral | | High | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024 |
MNPR Monopar Therapeutics | $35.16
+4.8% | 10/11/2024 | Initiated by | Rodman & Renshaw | - | Buy | $50.00 | High | View details for Rodman & Renshaw rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/11/2024 |
NKTX Nkarta | $1.74
+1.8% | 10/9/2024 | Initiated by | Rodman & Renshaw | - | Buy | $14.00 | Medium | View details for Rodman & Renshaw rating of Nkarta (NASDAQ:NKTX) on 10/9/2024 |
KYTX Kyverna Therapeutics | $2.83
+2.2% | 10/9/2024 | Initiated by | Rodman & Renshaw | - | Buy | $16.00 | High | View details for Rodman & Renshaw rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024 |
MIRA MIRA Pharmaceuticals | $1.24
+2.5% | 9/30/2024 | Initiated by | Rodman & Renshaw | - | Buy | $17.00 | High | View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024 |
BMEA Biomea Fusion | $1.65
-4.1% | 9/26/2024 | Upgraded by | Rodman & Renshaw | - | Neutral -> Buy | $18.00 | Medium | View details for Rodman & Renshaw rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024 |
EBS Emergent Biosolutions | $7.08
+7.3% | 9/13/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $16.00 -> $16.00 | Low | View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 9/13/2024 |
ATHA Athira Pharma | $0.30
+0.4% | 9/4/2024 | Downgraded by | Rodman & Renshaw | - | Buy -> Neutral | | Low | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 9/4/2024 |
PASG Passage Bio | $0.41
+6.9% | 9/3/2024 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Low | View details for Rodman & Renshaw rating of Passage Bio (NASDAQ:PASG) on 9/3/2024 |
CRMD CorMedix | $11.59
-1.7% | 8/26/2024 | Initiated by | Rodman & Renshaw | - | Buy | $13.00 | Low | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/26/2024 |
MIST Milestone Pharmaceuticals | $1.92
+2.1% | 8/22/2024 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | Low | View details for Rodman & Renshaw rating of Milestone Pharmaceuticals (NASDAQ:MIST) on 8/22/2024 |
DERM Journey Medical | $7.04
+1.0% | 8/22/2024 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | Low | View details for Rodman & Renshaw rating of Journey Medical (NASDAQ:DERM) on 8/22/2024 |
EBS Emergent Biosolutions | $7.08
+7.3% | 8/22/2024 | Initiated by | Rodman & Renshaw | - | Buy | $16.00 | Low | View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 8/22/2024 |
ATHA Athira Pharma | $0.30
+0.4% | 8/19/2024 | Initiated by | Rodman & Renshaw | - | Buy | $22.00 | Low | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 8/19/2024 |
SAVA Cassava Sciences | $2.01
+8.6% | 8/8/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $107.00 -> $107.00 | Low | View details for Rodman & Renshaw rating of Cassava Sciences (NASDAQ:SAVA) on 8/8/2024 |
IPSC Century Therapeutics | $0.56
+2.2% | 8/8/2024 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | Low | View details for Rodman & Renshaw rating of Century Therapeutics (NASDAQ:IPSC) on 8/8/2024 |
CRSP CRISPR Therapeutics | $51.67
+6.5% | 8/2/2024 | Initiated by | Rodman & Renshaw | - | Buy | $90.00 | Low | View details for Rodman & Renshaw rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/2/2024 |
ANVS Annovis Bio | $2.38
+2.1% | 7/2/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $67.00 -> $67.00 | Low | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 7/2/2024 |
CGTX Cognition Therapeutics | $0.34
+7.3% | 7/2/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $14.00 -> $14.00 | Low | View details for Rodman & Renshaw rating of Cognition Therapeutics (NASDAQ:CGTX) on 7/2/2024 |
NKTR Nektar Therapeutics | $25.53
+3.8% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $30.00 | Low | View details for Rodman & Renshaw rating of Nektar Therapeutics (NASDAQ:NKTR) on 6/28/2024 |
LPTX Leap Therapeutics | $0.29
-2.8% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | Low | View details for Rodman & Renshaw rating of Leap Therapeutics (NASDAQ:LPTX) on 6/28/2024 |
MURA Mural Oncology | $2.51
+0.4% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $15.00 | Low | View details for Rodman & Renshaw rating of Mural Oncology (NASDAQ:MURA) on 6/28/2024 |
SANA Sana Biotechnology | $2.92
+3.2% | 6/26/2024 | Initiated by | Rodman & Renshaw | - | Buy | $16.00 | Low | View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 6/26/2024 |
ANRO Alto Neuroscience | $2.33
+5.0% | 6/21/2024 | Initiated by | Rodman & Renshaw | - | Buy | $43.00 | Low | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 6/21/2024 |
COYA Coya Therapeutics | $5.78
+1.4% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $18.00 | Low | View details for Rodman & Renshaw rating of Coya Therapeutics (NASDAQ:COYA) on 6/13/2024 |
TRVI Trevi Therapeutics | $5.98
+4.9% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Low | View details for Rodman & Renshaw rating of Trevi Therapeutics (NASDAQ:TRVI) on 6/13/2024 |
Dalio heeds Buffett’s warning… [$319 million stake in gold] (Ad) Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts.
I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks.  Get Garrett’s Top Four gold picks now — before the world’s greatest investor pulls the trigger. |
SCLX Scilex | $6.24
+3.3% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $455.00 | Low | View details for Rodman & Renshaw rating of Scilex (NASDAQ:SCLX) on 6/13/2024 |
RANI Rani Therapeutics | $0.53
+3.6% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | Low | View details for Rodman & Renshaw rating of Rani Therapeutics (NASDAQ:RANI) on 6/13/2024 |
MNKD MannKind | $3.62
+1.1% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | Low | View details for Rodman & Renshaw rating of MannKind (NASDAQ:MNKD) on 6/13/2024 |
HRTX Heron Therapeutics | $2.15
-0.9% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Low | View details for Rodman & Renshaw rating of Heron Therapeutics (NASDAQ:HRTX) on 6/13/2024 |
AVDL Avadel Pharmaceuticals | $8.81
| 6/12/2024 | Initiated by | Rodman & Renshaw | - | Buy | $27.00 | Low | View details for Rodman & Renshaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 6/12/2024 |
ANVS Annovis Bio | $2.38
+2.1% | 6/4/2024 | Initiated by | Rodman & Renshaw | - | Buy | $67.00 | Low | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 6/4/2024 |
BHC Bausch Health Cos | $7.11
+4.7% | 8/10/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $17.00 | High | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 8/10/2017 |
CRMD CorMedix | $11.59
-1.7% | 8/10/2017 | Target Lowered by | Rodman & Renshaw | - | Buy -> Buy | $25.00 -> $15.00 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/10/2017 |
GEVO Gevo | $1.41
+6.0% | 8/9/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $240.00 | Medium | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/9/2017 |
POETF POET Technologies | $5.23
+0.4% | 8/7/2017 | Initiated by | Rodman & Renshaw | - | Buy | | High | View details for Rodman & Renshaw rating of POET Technologies (OTCMKTS:POETF) on 8/7/2017 |
VERU Veru | $0.58
-1.1% | 7/26/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $5.00 | High | View details for Rodman & Renshaw rating of Veru (NASDAQ:VERU) on 7/26/2017 |
PLUG Plug Power | $1.40
-0.7% | 7/24/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $4.00 | Low | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 7/24/2017 |
CAPR Capricor Therapeutics | $10.02
+3.3% | 7/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $2.15 | N/A | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 7/22/2017 |
BYSI BeyondSpring | $2.29
-5.4% | 7/14/2017 | Target Raised by | Rodman & Renshaw | - | Buy -> Buy | $43.00 -> $50.00 | Medium | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 7/14/2017 |
FBIO Fortress Biotech | $1.83
+0.5% | 7/11/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $165.00 | Low | View details for Rodman & Renshaw rating of Fortress Biotech (NASDAQ:FBIO) on 7/11/2017 |
EMAN eMagin | $2.07
| 6/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $4.00 | N/A | View details for Rodman & Renshaw rating of eMagin (NYSEAMERICAN:EMAN) on 6/23/2017 |
USA Americas Silver | C$1.15
+4.5% | 6/15/2017 | Initiated by | Rodman & Renshaw | - | Buy | C$4.00 | N/A | View details for Rodman & Renshaw rating of Americas Silver (TSE:USA) on 6/15/2017 |
USAS Americas Gold and Silver | $0.85
0.0% | 6/15/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $4.00 -> $4.00 | Medium | View details for Rodman & Renshaw rating of Americas Gold and Silver (NYSEAMERICAN:USAS) on 6/15/2017 |
EYPT Eyepoint Pharmaceuticals | $9.66
+1.2% | 5/30/2017 | Initiated by | Rodman & Renshaw | - | Buy | $800.00 | High | View details for Rodman & Renshaw rating of Eyepoint Pharmaceuticals (NASDAQ:EYPT) on 5/30/2017 |
PLX Protalix BioTherapeutics | $1.50
+1.4% | 5/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 5/23/2017 |
ACAD ACADIA Pharmaceuticals | $21.24
-0.6% | 5/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $60.00 | Low | View details for Rodman & Renshaw rating of ACADIA Pharmaceuticals (NASDAQ:ACAD) on 5/22/2017 |
BHC Bausch Health Cos | $7.11
+4.7% | 5/19/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $17.00 | Medium | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 5/19/2017 |
MGIC Magic Software Enterprises | $20.33
+3.4% | 5/17/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $9.00 -> $10.00 | Medium | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 5/17/2017 |
IOVA Iovance Biotherapeutics | $1.75
+0.6% | 5/10/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $13.00 | Low | View details for Rodman & Renshaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/10/2017 |
CRMD CorMedix | $11.59
-1.7% | 5/5/2017 | Target Lowered by | Rodman & Renshaw | - | Buy | $30.00 -> $25.00 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 5/5/2017 |
AMSC American Superconductor | $39.19
+8.9% | 4/28/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $10.00 -> $7.50 | High | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/28/2017 |
B Barrick Mining | $21.24
+1.9% | 4/24/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $4.25 -> $4.50 | N/A | View details for Rodman & Renshaw rating of Barrick Mining (NYSE:B) on 4/24/2017 |
PLX Protalix BioTherapeutics | $1.50
+1.4% | 4/17/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $40.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
PLX Protalix BioTherapeutics | $1.50
+1.4% | 4/17/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $40.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
WRN Western Copper and Gold | C$1.74
+4.2% | 4/10/2017 | Reiterated by | Rodman & Renshaw | - | Buy | C$2.00 | N/A | View details for Rodman & Renshaw rating of Western Copper and Gold (TSE:WRN) on 4/10/2017 |
WRN Western Copper and Gold | $1.28
+2.4% | 4/7/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $2.00 | Medium | View details for Rodman & Renshaw rating of Western Copper and Gold (NYSEAMERICAN:WRN) on 4/7/2017 |
PLUG Plug Power | $1.40
-0.7% | 4/6/2017 | Target Raised by | Rodman & Renshaw | - | Buy -> Buy | $3.00 -> $4.00 | High | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 4/6/2017 |
BYSI BeyondSpring | $2.29
-5.4% | 4/4/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $43.00 | Low | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 4/4/2017 |
CYTK Cytokinetics | $34.36
+2.1% | 3/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $25.00 | Medium | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/23/2017 |
HROW Harrow | $30.57
-0.6% | 3/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $5.00 | High | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 3/22/2017 |
MAG MAG Silver | $21.37
+1.2% | 3/9/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $20.00 -> $20.50 | Low | View details for Rodman & Renshaw rating of MAG Silver (NYSEAMERICAN:MAG) on 3/9/2017 |
CYTK Cytokinetics | $34.36
+2.1% | 3/8/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $25.00 | High | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/8/2017 |
BHC Bausch Health Cos | $7.11
+4.7% | 3/6/2017 | Target Lowered by | Rodman & Renshaw | - | Neutral | $23.00 -> $17.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/6/2017 |
MGIC Magic Software Enterprises | $20.33
+3.4% | 3/6/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $8.00 -> $9.00 | N/A | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 3/6/2017 |
QRHC Quest Resource | $2.14
+8.1% | 3/6/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $5.00 | N/A | View details for Rodman & Renshaw rating of Quest Resource (NASDAQ:QRHC) on 3/6/2017 |
BHC Bausch Health Cos | $7.11
+4.7% | 2/27/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $23.00 -> $17.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/27/2017 |
CAPR Capricor Therapeutics | $10.02
+3.3% | 2/13/2017 | Initiated by | Rodman & Renshaw | - | Buy | $14.00 | N/A | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 2/13/2017 |
BLRX BioLineRx | $4.61
+1.8% | 2/13/2017 | Initiated by | Rodman & Renshaw | - | Buy | $120.00 | N/A | View details for Rodman & Renshaw rating of BioLineRx (NASDAQ:BLRX) on 2/13/2017 |
ABEO Abeona Therapeutics | $5.87
+5.4% | 2/7/2017 | Reiterated by | Rodman & Renshaw | Analyst ram selvaraju | Buy | $425.00 -> $500.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 2/7/2017 |
BHC Bausch Health Cos | $7.11
+4.7% | 1/31/2017 | Downgraded by | Rodman & Renshaw | - | Buy -> Neutral | | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 1/31/2017 |
ASM Avino Silver & Gold Mines | $3.37
-2.9% | 1/24/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $3.50 -> $4.00 | N/A | View details for Rodman & Renshaw rating of Avino Silver & Gold Mines (NYSE:ASM) on 1/24/2017 |
PLUG Plug Power | $1.40
-0.7% | 12/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $3.00 | N/A | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 12/6/2016 |
B Barrick Mining | $21.24
+1.9% | 11/28/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $4.00 -> $4.25 | N/A | View details for Rodman & Renshaw rating of Barrick Mining (NYSE:B) on 11/28/2016 |
HROW Harrow | $30.57
-0.6% | 11/28/2016 | Initiated by | Rodman & Renshaw | - | Buy | $5.00 | N/A | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 11/28/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 11/10/2016 | Downgraded by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy -> Neutral | $81.00 -> $23.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 11/10/2016 |
This Signal Only Flashes Once Every 4 Years – And It Just Triggered (Ad) This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto.
Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave. Missed the Last Crypto Boom? Don’t Miss This One - PLUS Claim your $10 in Bitcoin |
GGD GoGold Resources | C$2.04
+2.0% | 10/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | C$3.50 -> C$3.00 | N/A | View details for Rodman & Renshaw rating of GoGold Resources (TSE:GGD) on 10/7/2016 |
CYDY CytoDyn | $0.27
-2.2% | 10/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $1.60 | N/A | View details for Rodman & Renshaw rating of CytoDyn (OTCMKTS:CYDY) on 10/6/2016 |
TGEN Tecogen | $9.13
+29.0% | 10/4/2016 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | N/A | View details for Rodman & Renshaw rating of Tecogen (OTCMKTS:TGEN) on 10/4/2016 |
DRRX DURECT | $0.67
+4.2% | 9/27/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 -> $35.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 9/27/2016 |
AYTU Aytu BioPharma | $2.29
+1.3% | 9/26/2016 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Aytu BioPharma (NASDAQ:AYTU) on 9/26/2016 |
CLNE Clean Energy Fuels | $2.09
+5.6% | 9/23/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $5.00 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Clean Energy Fuels (NASDAQ:CLNE) on 9/23/2016 |
UUUU Energy Fuels | $6.26
+8.9% | 9/22/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $5.00 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSEAMERICAN:UUUU) on 9/22/2016 |
UUUU Energy Fuels | $6.26
+8.9% | 9/22/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $6.30 -> $5.00 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSEAMERICAN:UUUU) on 9/22/2016 |
VNRX VolitionRX | $0.75
-2.1% | 9/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $12.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 9/7/2016 |
VNRX VolitionRX | $0.75
-2.1% | 9/7/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 9/7/2016 |
MEEC Midwest Energy Emissions | $0.70
+3.0% | 9/7/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Midwest Energy Emissions (OTCMKTS:MEEC) on 9/7/2016 |
HL Hecla Mining | $6.02
+0.8% | 9/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Hecla Mining (NYSE:HL) on 9/6/2016 |
REI Ring Energy | $0.81
+2.5% | 8/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $15.00 | N/A | View details for Rodman & Renshaw rating of Ring Energy (NYSEAMERICAN:REI) on 8/29/2016 |
DRIO DarioHealth | $0.71
+0.0% | 8/22/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 8/22/2016 |
ORMP Oramed Pharmaceuticals | $2.16
+2.9% | 8/21/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 8/21/2016 |
ABEO Abeona Therapeutics | $5.87
+5.4% | 8/21/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/21/2016 |
SMT Sierra Metals | C$1.15
+0.9% | 8/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | C$3.00 | N/A | View details for Rodman & Renshaw rating of Sierra Metals (TSE:SMT) on 8/18/2016 |
EFOI Energy Focus | $2.38
+1.3% | 8/15/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $280.00 -> $560.00 | N/A | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 8/15/2016 |
OPGN OpGen | $4.73
-0.6% | 8/10/2016 | Target Set by | Rodman & Renshaw | Analyst yi chen | Buy | $825.00 | N/A | View details for Rodman & Renshaw rating of OpGen (NASDAQ:OPGN) on 8/10/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 8/9/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 -> $81.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 8/9/2016 |
ABEO Abeona Therapeutics | $5.87
+5.4% | 8/5/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/5/2016 |
DRRX DURECT | $0.67
+4.2% | 8/3/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 8/3/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 7/28/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/28/2016 |
KURA Kura Oncology | $5.81
+3.8% | 7/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 7/18/2016 |
F Ford Motor | $11.77
+3.7% | 7/18/2016 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ford Motor (NYSE:F) on 7/18/2016 |
OESX Orion Energy Systems | $0.59
-1.7% | 7/18/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Orion Energy Systems (NASDAQ:OESX) on 7/18/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 7/17/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/17/2016 |
PLX Protalix BioTherapeutics | $1.50
+1.4% | 7/11/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 7/11/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 7/6/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/6/2016 |
DRRX DURECT | $0.67
+4.2% | 7/6/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 7/6/2016 |
CBIO Crescent Biopharma | $15.55
-3.7% | 6/30/2016 | Initiated by | Rodman & Renshaw | - | Buy | $5,250.00 | N/A | View details for Rodman & Renshaw rating of Crescent Biopharma (NASDAQ:CBIO) on 6/30/2016 |
OPGN OpGen | $4.73
-0.6% | 6/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $625.00 | N/A | View details for Rodman & Renshaw rating of OpGen (NASDAQ:OPGN) on 6/29/2016 |
INO Inovio Pharmaceuticals | $2.14
+4.9% | 6/21/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $2,448.00 | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 6/21/2016 |
WPRT Westport Fuel Systems | $3.11
| 6/20/2016 | Initiated by | Rodman & Renshaw | - | Buy | $50.00 | N/A | View details for Rodman & Renshaw rating of Westport Fuel Systems (NASDAQ:WPRT) on 6/20/2016 |
VNRX VolitionRX | $0.75
-2.1% | 6/16/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 6/16/2016 |
KURA Kura Oncology | $5.81
+3.8% | 5/24/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 5/24/2016 |
DRIO DarioHealth | $0.71
+0.0% | 5/24/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/24/2016 |
ABEO Abeona Therapeutics | $5.87
+5.4% | 5/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 5/18/2016 |
VNRX VolitionRX | $0.75
-2.1% | 5/16/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 5/16/2016 |
DRRX DURECT | $0.67
+4.2% | 5/13/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 5/13/2016 |
ORMP Oramed Pharmaceuticals | $2.16
+2.9% | 5/13/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 5/13/2016 |
MBOT Microbot Medical | $2.50
+0.4% | 5/10/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 5/10/2016 |
DRIO DarioHealth | $0.71
+0.0% | 5/9/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/9/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 5/3/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $105.00 -> $102.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 5/3/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 4/26/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $105.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/26/2016 |
DRRX DURECT | $0.67
+4.2% | 4/25/2016 | Initiated by | Rodman & Renshaw | - | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 4/25/2016 |
VNRX VolitionRX | $0.75
-2.1% | 4/21/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 4/21/2016 |
ABEO Abeona Therapeutics | $5.87
+5.4% | 4/20/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 4/20/2016 |
MBOT Microbot Medical | $2.50
+0.4% | 4/20/2016 | Initiated by | Rodman & Renshaw | - | Buy | $18.00 | N/A | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 4/20/2016 |
AG First Majestic Silver | $8.50
+1.7% | 4/15/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $6.00 -> $8.75 | N/A | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 4/15/2016 |
This Signal Only Flashes Once Every 4 Years – And It Just Triggered (Ad) This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto.
Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave. Missed the Last Crypto Boom? Don’t Miss This One - PLUS Claim your $10 in Bitcoin |
SMLR Semler Scientific | $39.54
+11.6% | 4/15/2016 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | N/A | View details for Rodman & Renshaw rating of Semler Scientific (NASDAQ:SMLR) on 4/15/2016 |
EXK Endeavour Silver | $5.07
+0.4% | 4/12/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $2.50 -> $3.40 | N/A | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 4/12/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 4/11/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $118.00 -> $105.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/11/2016 |
INO Inovio Pharmaceuticals | $2.14
+4.9% | 4/9/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 4/9/2016 |
VNRX VolitionRX | $0.75
-2.1% | 4/9/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 4/9/2016 |
KURA Kura Oncology | $5.81
+3.8% | 4/4/2016 | Initiated by | Rodman & Renshaw | - | Buy | $52,500.00 | N/A | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 4/4/2016 |
PLX Protalix BioTherapeutics | $1.50
+1.4% | 4/4/2016 | Initiated by | Rodman & Renshaw | - | Buy | $35.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/4/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 4/3/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/3/2016 |
AMSC American Superconductor | $39.19
+8.9% | 4/1/2016 | Reiterated by | Rodman & Renshaw | Analyst Amit Dayal | Neutral | | N/A | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/1/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 3/28/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $118.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/28/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 3/22/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/22/2016 |
NNDM Nano Dimension | $1.55
-0.6% | 3/21/2016 | Initiated by | Rodman & Renshaw | - | Buy | $700.00 | N/A | View details for Rodman & Renshaw rating of Nano Dimension (NASDAQ:NNDM) on 3/21/2016 |
INO Inovio Pharmaceuticals | $2.14
+4.9% | 3/20/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 3/20/2016 |
UUUU Energy Fuels | $6.26
+8.9% | 3/17/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $6.90 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSEAMERICAN:UUUU) on 3/17/2016 |
CRMD CorMedix | $11.59
-1.7% | 3/17/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $32.50 -> $37.50 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 3/17/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 3/16/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $150.00 -> $118.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/16/2016 |
MUX McEwen Mining | $10.99
-0.1% | 3/14/2016 | Target Raised by | Rodman & Renshaw | - | | $13.00 -> $24.00 | N/A | View details for Rodman & Renshaw rating of McEwen Mining (NYSE:MUX) on 3/14/2016 |
VNRX VolitionRX | $0.75
-2.1% | 3/14/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 3/14/2016 |
INSG Inseego | $8.68
-1.7% | 3/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $60.00 -> $30.00 | N/A | View details for Rodman & Renshaw rating of Inseego (NASDAQ:INSG) on 3/7/2016 |
PLM PolyMet Mining | $2.10
-0.5% | 3/4/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $2.00 -> $2.40 | N/A | View details for Rodman & Renshaw rating of PolyMet Mining (NYSEAMERICAN:PLM) on 3/4/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 3/2/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/2/2016 |
AG First Majestic Silver | $8.50
+1.7% | 2/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | N/A | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 2/29/2016 |
EXK Endeavour Silver | $5.07
+0.4% | 2/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 2/29/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 2/23/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $150.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/23/2016 |
RDCM Radcom | $13.58
-1.2% | 2/18/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $12.00 -> $16.00 | N/A | View details for Rodman & Renshaw rating of Radcom (NASDAQ:RDCM) on 2/18/2016 |
BHC Bausch Health Cos | $7.11
+4.7% | 2/16/2016 | Initiated by | Rodman & Renshaw | - | Buy | $150.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/16/2016 |
TMQ Trilogy Metals | $1.38
-0.7% | 2/11/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $1.40 -> $1.30 | N/A | View details for Rodman & Renshaw rating of Trilogy Metals (NYSEAMERICAN:TMQ) on 2/11/2016 |
TMQ Trilogy Metals | $1.38
-0.7% | 2/10/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $1.40 -> $1.30 | N/A | View details for Rodman & Renshaw rating of Trilogy Metals (NYSEAMERICAN:TMQ) on 2/10/2016 |
BCRX BioCryst Pharmaceuticals | $9.02
+0.2% | 2/9/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $24.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) on 2/9/2016 |
VNRX VolitionRX | $0.75
-2.1% | 2/1/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 2/1/2016 |
INO Inovio Pharmaceuticals | $2.14
+4.9% | 1/29/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 1/29/2016 |
IPWR Ideal Power | $4.49
+0.2% | 1/26/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of Ideal Power (NASDAQ:IPWR) on 1/26/2016 |
AMSC American Superconductor | $39.19
+8.9% | 1/13/2016 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | N/A | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 1/13/2016 |
ORMP Oramed Pharmaceuticals | $2.16
+2.9% | 1/10/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 1/10/2016 |
GGD GoGold Resources | C$2.04
+2.0% | 12/21/2015 | Target Raised by | Rodman & Renshaw | - | | C$2.70 -> C$2.90 | N/A | View details for Rodman & Renshaw rating of GoGold Resources (TSE:GGD) on 12/21/2015 |
MVIS Microvision | $1.11
+0.9% | 12/17/2015 | Initiated by | Rodman & Renshaw | - | Buy | $3.50 | N/A | View details for Rodman & Renshaw rating of Microvision (NASDAQ:MVIS) on 12/17/2015 |
CRMD CorMedix | $11.59
-1.7% | 12/16/2015 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 12/16/2015 |
VUZI Vuzix | $2.81
+3.3% | 12/10/2015 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | N/A | View details for Rodman & Renshaw rating of Vuzix (NASDAQ:VUZI) on 12/10/2015 |
CRMD CorMedix | $11.59
-1.7% | 11/12/2015 | Initiated by | Rodman & Renshaw | - | Buy | $32.50 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 11/12/2015 |
BLDP Ballard Power Systems | $1.67
+3.7% | 10/5/2015 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 10/5/2015 |
ORMP Oramed Pharmaceuticals | $2.16
+2.9% | 10/1/2015 | Initiated by | Rodman & Renshaw | - | Buy | $24.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 10/1/2015 |
BLDP Ballard Power Systems | $1.67
+3.7% | 8/20/2015 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 8/20/2015 |
GEVO Gevo | $1.41
+6.0% | 8/19/2015 | Initiated by | Rodman & Renshaw | - | Buy | $100.00 | N/A | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/19/2015 |
EFOI Energy Focus | $2.38
+1.3% | 8/7/2015 | Initiated by | Rodman & Renshaw | - | Buy | $630.00 | N/A | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 8/7/2015 |
BLDP Ballard Power Systems | $1.67
+3.7% | 7/14/2015 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 7/14/2015 |
EFOI Energy Focus | $2.38
+1.3% | 6/25/2015 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 6/25/2015 |
CPRX Catalyst Pharmaceuticals | $21.45
+1.2% | 8/27/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $3.70 | N/A | View details for Rodman & Renshaw rating of Catalyst Pharmaceuticals (NASDAQ:CPRX) on 8/27/2012 |
CYTK Cytokinetics | $34.36
+2.1% | 7/31/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $2.00 | N/A | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 7/31/2012 |
ALNY Alnylam Pharmaceuticals | $329.77
+2.4% | 7/31/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $22.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/31/2012 |
BMY Bristol Myers Squibb | $47.64
+0.3% | 7/27/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $38.00 -> $39.50 | N/A | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 7/27/2012 |
Dalio heeds Buffett’s warning… [$319 million stake in gold] (Ad) Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts.
I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks. Get Garrett’s Top Four gold picks now — before the world’s greatest investor pulls the trigger. |
AMGN Amgen | $296.85
+2.2% | 7/23/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $73.00 -> $89.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 7/23/2012 |
ALNY Alnylam Pharmaceuticals | $329.77
+2.4% | 7/16/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/16/2012 |
ALGT Allegiant Travel | $59.08
+1.2% | 7/13/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $72.00 -> $79.00 | N/A | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 7/13/2012 |
BMY Bristol Myers Squibb | $47.64
+0.3% | 7/5/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | $38.00 | N/A | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 7/5/2012 |
ASMB Assembly Biosciences | $18.30
+3.2% | 6/26/2012 | Target Lowered by | Rodman & Renshaw | - | | $132.00 | N/A | View details for Rodman & Renshaw rating of Assembly Biosciences (NASDAQ:ASMB) on 6/26/2012 |
RPMT Virtual Piggy | $0.54
+0.4% | 6/25/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $5.00 | N/A | View details for Rodman & Renshaw rating of Virtual Piggy (OTCMKTS:RPMT) on 6/25/2012 |
AMGN Amgen | $296.85
+2.2% | 6/21/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $57.00 -> $73.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 6/21/2012 |
MNOV MediciNova | $1.27
| 6/19/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of MediciNova (NASDAQ:MNOV) on 6/19/2012 |
DCO Ducommun | $82.96
+0.3% | 5/24/2012 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Ducommun (NYSE:DCO) on 5/24/2012 |
POWL Powell Industries | $218.53
+4.0% | 5/10/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $43.00 | N/A | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 5/10/2012 |
NPO Enpro | $201.44
+3.2% | 5/4/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $47.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Enpro (NYSE:NPO) on 5/4/2012 |
RMTI Rockwell Medical | $0.82
-1.5% | 4/24/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $176.00 | N/A | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 4/24/2012 |
SYK Stryker | $391.98
-1.2% | 4/20/2012 | Downgraded by | Rodman & Renshaw | - | Outperform -> Market Perform | | N/A | View details for Rodman & Renshaw rating of Stryker (NYSE:SYK) on 4/20/2012 |
PODD Insulet | $301.62
+0.5% | 4/18/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | | N/A | View details for Rodman & Renshaw rating of Insulet (NASDAQ:PODD) on 4/18/2012 |
TRS TriMas | $29.76
+2.4% | 3/15/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $32.00 | N/A | View details for Rodman & Renshaw rating of TriMas (NASDAQ:TRS) on 3/15/2012 |
OMER Omeros | $3.09
+4.0% | 3/13/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $13.00 -> $16.00 | N/A | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 3/13/2012 |
AMGN Amgen | $296.85
+2.2% | 3/7/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 3/7/2012 |
VSTM Verastem | $4.85
+13.1% | 3/7/2012 | Initiated by | Rodman & Renshaw | - | Buy -> Market Perform | | N/A | View details for Rodman & Renshaw rating of Verastem (NASDAQ:VSTM) on 3/7/2012 |
ANIP ANI Pharmaceuticals | $65.22
+2.6% | 2/27/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 2/27/2012 |
MDGL Madrigal Pharmaceuticals | $300.15
0.0% | 2/22/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | $8.00 | N/A | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 2/22/2012 |
MGIC Magic Software Enterprises | $20.33
+3.4% | 2/15/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $8.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 2/15/2012 |
ALNY Alnylam Pharmaceuticals | $329.77
+2.4% | 2/6/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $19.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/6/2012 |
DAL Delta Air Lines | $50.10
+2.2% | 2/6/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $14.00 | N/A | View details for Rodman & Renshaw rating of Delta Air Lines (NYSE:DAL) on 2/6/2012 |
ALGT Allegiant Travel | $59.08
+1.2% | 2/2/2012 | Target Raised by | Rodman & Renshaw | - | | $62.00 | N/A | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 2/2/2012 |
POWL Powell Industries | $218.53
+4.0% | 1/26/2012 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 1/26/2012 |
SILC Silicom | $15.45
+0.1% | 1/24/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $20.00 -> $25.00 | N/A | View details for Rodman & Renshaw rating of Silicom (NASDAQ:SILC) on 1/24/2012 |
BMY Bristol Myers Squibb | $47.64
+0.3% | 1/23/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $51.00 | N/A | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 1/23/2012 |
LUV Southwest Airlines | $33.99
+1.7% | 1/20/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 1/20/2012 |
AMGN Amgen | $296.85
+2.2% | 1/17/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 1/17/2012 |
MDGL Madrigal Pharmaceuticals | $300.15
0.0% | 1/5/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $8.00 | N/A | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 1/5/2012 |
ALNY Alnylam Pharmaceuticals | $329.77
+2.4% | 1/4/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/4/2012 |
WWD Woodward | $248.82
+1.8% | 1/4/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $52.00 | N/A | View details for Rodman & Renshaw rating of Woodward (NASDAQ:WWD) on 1/4/2012 |
AMGN Amgen | $296.85
+2.2% | 12/23/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/23/2011 |
ANIP ANI Pharmaceuticals | $65.22
+2.6% | 12/15/2011 | Downgraded by | Rodman & Renshaw | - | Outperform -> Market Perform | | N/A | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/15/2011 |
INTC Intel | $21.88
-4.2% | 12/13/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $27.00 | N/A | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 12/13/2011 |
BMY Bristol Myers Squibb | $47.64
+0.3% | 12/13/2011 | Target Lowered by | Rodman & Renshaw | - | | $51.00 | N/A | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 12/13/2011 |
ALNY Alnylam Pharmaceuticals | $329.77
+2.4% | 12/12/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/12/2011 |
BMY Bristol Myers Squibb | $47.64
+0.3% | 12/12/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $52.50 | N/A | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 12/12/2011 |
OMER Omeros | $3.09
+4.0% | 12/5/2011 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $13.00 | N/A | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 12/5/2011 |
ROG Rogers | $73.31
+3.1% | 12/2/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $55.00 | N/A | View details for Rodman & Renshaw rating of Rogers (NYSE:ROG) on 12/2/2011 |
ALNY Alnylam Pharmaceuticals | $329.77
+2.4% | 12/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/1/2011 |
AMGN Amgen | $296.85
+2.2% | 12/1/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $62.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/1/2011 |
CRIS Curis | $1.75
-18.6% | 11/30/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $600.00 | N/A | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/30/2011 |
EW Edwards Lifesciences | $77.03
-0.2% | 11/29/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/29/2011 |
AAPL Apple | $212.44
+2.2% | 11/29/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $16.07 | N/A | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/29/2011 |
LUV Southwest Airlines | $33.99
+1.7% | 11/21/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 11/21/2011 |
DELL Dell Technologies | $123.50
+1.5% | 11/15/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $18.00 | N/A | View details for Rodman & Renshaw rating of Dell Technologies (NYSE:DELL) on 11/15/2011 |
EW Edwards Lifesciences | $77.03
-0.2% | 11/11/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/11/2011 |
ADNT Adient | $22.18
+5.4% | 11/11/2011 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Adient (NYSE:ADNT) on 11/11/2011 |
ALNY Alnylam Pharmaceuticals | $329.77
+2.4% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/10/2011 |
INTC Intel | $21.88
-4.2% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 11/10/2011 |
CRIS Curis | $1.75
-18.6% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $600.00 | N/A | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/10/2011 |
AAPL Apple | $212.44
+2.2% | 11/9/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/9/2011 |
GERN Geron | $1.40
+1.4% | 11/9/2011 | Target Lowered by | Rodman & Renshaw | - | | $4.00 | N/A | View details for Rodman & Renshaw rating of Geron (NASDAQ:GERN) on 11/9/2011 |
BMY Bristol Myers Squibb | $47.64
+0.3% | 11/9/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $52.50 | N/A | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 11/9/2011 |
USEG U.S. Energy | $1.37
| 11/8/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $47.50 | N/A | View details for Rodman & Renshaw rating of U.S. Energy (NASDAQ:USEG) on 11/8/2011 |
ERII Energy Recovery | $12.88
+1.3% | 11/4/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Energy Recovery (NASDAQ:ERII) on 11/4/2011 |
AUDC AudioCodes | $9.76
+1.5% | 11/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of AudioCodes (NASDAQ:AUDC) on 11/1/2011 |
CYTK Cytokinetics | $34.36
+2.1% | 11/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $4.00 | N/A | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 11/1/2011 |
ALNY Alnylam Pharmaceuticals | $329.77
+2.4% | 11/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/1/2011 |
